VICL - Vical Incorporated

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Vical Incorporated

10390 Pacific Center Court
San Diego, CA 92121
United States

Full Time Employees74

Key Executives

NameTitlePayExercisedYear Born
Mr. Vijay B. SamantCEO, Pres & Director905.94kN/A1953
Mr. Anthony Alan RamosVP, CFO & Chief Accounting Officer336.63kN/A1967
Dr. Lawrence Russell SmithSr. VP of Research360.95kN/A1961
Dr. Mammen P. Mammen Jr.Sr. VP of Clinical Devel.N/AN/A1964
Mr. Keith D. HallVP of OperationsN/AN/A1962
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Vical Incorporated engages in the research and development of biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. The company is developing VCL-HB01, an HSV-2 therapeutic vaccine that is in Phase II clinical trial to prevent and protect against lesion recurrence, as well as for the treatment of patients with symptomatic genital herpes infection; VL-2397 antifungal program, which is in Phase II clinical trial for the treatment of invasive fungal infections; and chronic hepatitis B that is in preclinical stage for the eradication of persistent HBV infection. Vical Incorporated has a license agreement with Astellas Pharma Inc. to develop and commercialize VL-2397 antifungal candidate. The company was founded in 1987 and is headquartered in San Diego, California.

Corporate Governance

Vical Incorporated’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.